The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subgroup analyses of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor in RINDBeRG: A randomized clinical trial in third- or further-line treatment of gastric cancer.
 
Ryohei Kawabata
No Relationships to Disclose
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/UCB Japan
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo; Eisai (Inst); Incyte (Inst); Lilly Japan; Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Merck KGaA; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst)
 
Takao Tsuduki
No Relationships to Disclose
 
Takahisa Suzuki
No Relationships to Disclose
 
Toru Masuzawa
No Relationships to Disclose
 
Keitaro Shimozaki
No Relationships to Disclose
 
Masahiro Tsuda
No Relationships to Disclose
 
Takeshi Yamada
Speakers' Bureau - Bristol-Myers Squibb Company; DAIICHI SANKYO COMPANY; Lilly Japan; ONO PHARMACEUTICAL
 
Toshifumi Yamaguchi
Employment - Chugai Pharma; Ono Pharmaceutical; Yakult Honsha
 
Shugo Ueda
No Relationships to Disclose
 
Yosuke Kito
Honoraria - Daiichi Sakyo; Ono Pharmaceutical; Taiho Pharmaceutical
 
Toshiharu Hirose
No Relationships to Disclose
 
Tomono Kawase
No Relationships to Disclose
 
Takashi Nomura
No Relationships to Disclose
 
Kazuhiro Nishikawa
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst)
 
Toshio Shimokawa
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Daiichi-Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)